Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/207224
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vincenzi, Bruno | - |
dc.contributor.author | Cortellini, Alessio | - |
dc.contributor.author | Mazzocca, Alessandro | - |
dc.contributor.author | Orlando, Sarah | - |
dc.contributor.author | Romandini, Davide | - |
dc.contributor.author | Aguilar Company, Juan | - |
dc.contributor.author | Ruiz Camps, Isabel | - |
dc.contributor.author | Valverde Morales, Claudia | - |
dc.contributor.author | Eremiev Eremiev, Simeon | - |
dc.contributor.author | Tondini, Carlo | - |
dc.contributor.author | Brunet, Joan | - |
dc.contributor.author | Bertulli, Rossella | - |
dc.contributor.author | Provenzano, Salvatore | - |
dc.contributor.author | Bower, Mark | - |
dc.contributor.author | Generali, Daniele | - |
dc.contributor.author | Salazar, Ramon | - |
dc.contributor.author | Sureda, Anna | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.contributor.author | Vasiliki, Michalarea | - |
dc.contributor.author | Hemelrijck, Mieke Van | - |
dc.contributor.author | Sita Lumsden, Ailsa | - |
dc.contributor.author | Bertuzzi, Alexia | - |
dc.contributor.author | Rossi, Sabrina | - |
dc.contributor.author | Jackson, Amanda | - |
dc.contributor.author | Grosso, Federica | - |
dc.contributor.author | Lee, Alvin J. X. | - |
dc.contributor.author | Murphy, Cian | - |
dc.contributor.author | Belessiotis, Katherine | - |
dc.contributor.author | Mukherjee, Uma | - |
dc.contributor.author | Pommeret, Fanny | - |
dc.contributor.author | Loizidou, Angela | - |
dc.contributor.author | Gaidano, Gianluca | - |
dc.contributor.author | Dettorre, Gino M. | - |
dc.contributor.author | Grisanti, Salvatore | - |
dc.contributor.author | Tucci, Marco | - |
dc.contributor.author | Fulgenzi, Claudia A. M. | - |
dc.contributor.author | Gennari, Alessandra | - |
dc.contributor.author | Napolitano, Andrea | - |
dc.contributor.author | Pinato, David J. | - |
dc.date.accessioned | 2024-02-06T12:08:30Z | - |
dc.date.available | 2024-02-06T12:08:30Z | - |
dc.date.issued | 2024-01-18 | - |
dc.identifier.issn | 1758-8359 | - |
dc.identifier.uri | http://hdl.handle.net/2445/207224 | - |
dc.description.abstract | Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population.Methods: We described COVID-19 morbidity and mortality among patients with STS across 'Omicron' (15 December 2021-31 January 2022), 'Pre-vaccination' (27 February 2020-30 November 2020), and 'Alpha-Delta' phase (01 December 2020-14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR28) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders.Results: Out of 3820 patients, 97 patients with STS were included. The median age at COVID-19 diagnosis was 56 years (range: 18-92), with 65 patients (67%) aged < 65 years and most patients had a low comorbidity burden (65, 67.0%). The most frequent primary tumor sites were the abdomen (56.7%) and the gynecological tract (12.4%). In total, 36 (37.1%) patients were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications, and 32.3% of hospitalizations due to COVID-19. CFR28 (29.5%, 21.4%, and 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated patients demonstrated numerically improved CFR28 (16.7% versus 27.7%) and COVID-19 morbidity compared with unvaccinated patients. Patients who were on chemotherapy experienced comparable CFR28 (19.4% versus 26.0%, p = 0.4803), hospitalizations (50.0% versus 44.4%, p = 0.6883), complication rates (30.6% versus 34.0%, p = 0.7381), and oxygen therapy requirement (28.1% versus 40.0%, p = 0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis.Conclusion: In this study, we demonstrate an improvement in COVID-19 outcomes in patients with STS over time. Recent exposure to chemotherapy does not impact COVID-19 morbidity and mortality and SARS-CoV-2 vaccination confers protection against adverse outcomes from COVID-19 in this patient population. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | SAGE Publications | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1177/17588359231225028 | - |
dc.relation.ispartof | Therapeutic Advances in Medical Oncology, 2024, vol. 16 | - |
dc.relation.uri | https://doi.org/10.1177/17588359231225028 | - |
dc.rights | cc by-nc (c) Vincenzi, Bruno et al., 2024 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.classification | Quimioteràpia | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | Chemotherapy | - |
dc.title | Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2024-02-05T08:12:23Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 38249336 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
vincenzi-et-al-2024-impact-of-sars-cov-2-vaccines-and-recent-chemotherapy-on-covid-19-morbidity-and-mortality-in.pdf | 874.6 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License